Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Next Previous
Trial Profile

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary) ; Carboplatin; Cisplatin; Doxorubicin liposomal; Etoposide; Gemcitabine; Irinotecan; Paclitaxel; Pemetrexed; Taxanes; Vinorelbine
  • Indications Carcinoma; Fallopian tube cancer; Gastrointestinal cancer; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms QUADRUPLE THREAT; TRIPLE THREAT
  • Sponsors EpicentRx

Most Recent Events

  • 18 Feb 2023 Results (n=90 with small cell cancer , high-grade neuroendocrine carcinoma, non-small cell lung cancer and genitourinary cancer ) assessing Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors presented at the 2023 Genitourinary Cancers Symposium
  • 15 Feb 2023 According to an EpicentRx media release, data from this trial will be presented as a poster at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO).
  • 06 Oct 2022 According to an EpicentRx media release, Primary endpoint (Overall Survival) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top